Nomogram based on preoperative CT imaging predicts the EGFR mutation status in lung adenocarcinoma
-
Published:2021-01
Issue:1
Volume:14
Page:100954
-
ISSN:1936-5233
-
Container-title:Translational Oncology
-
language:en
-
Short-container-title:Translational Oncology
Author:
Zhang Guojin,
Zhang Jing,
Cao Yuntai,
Zhao Zhiyong,
Li Shenglin,
Deng Liangna,
Zhou JunlinORCID
Subject
Cancer Research,Oncology
Reference40 articles.
1. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study;Sequist;Lancet Oncol.,2020
2. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer;Robichaux;Nat. Med.,2018
3. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer;Wu;Mol. Cancer,2018
4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol.,2012
5. CT features associated with epidermal growth factor receptor mutation status in patients with lung adenocarcinoma;Liu;Radiology,2016
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献